In 1992, it was first described to induce an efficient and complete response in patients suffering from acute promyelocytic leukemia (APL)46, 47, 48 prior to approval by the U.S. Food and Drug Administration (FDA) for APL treatment in 2000.49 In APL disease, PML (the main component of PML‐NBs) is fused to the retinoic acid receptor alpha (RARA) due to a chromosomal translocation. The gene discussed is PML; the disease is acute promyelocytic leukemia.